Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialYolanda Barbáchano, Ian Chau, David Cunningham et al.|The Lancet Oncology|2013Cited by 728
Targeted prostate cancer screening in men with mutations in <i>BRCA1</i> and <i>BRCA2</i> detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT studyAnita Mitra, Alison Falconer, Graeme Suthers et al.|British Journal of Urology|2010Cited by 98
Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumoursS.A. Sohaib, Robert Huddart, Dow‐Mu Koh et al.|Clinical Radiology|2008Cited by 97
A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).Tom Samuel Waddell, David Cunningham, Ian Chau et al.|Journal of Clinical Oncology|2012Cited by 49
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trialsAlicia Okines, Andrew Wotherspoon, David González de Castro et al.|European Journal of Cancer|2013Cited by 40